SCHEMBL4992165

SCHEMBL4992165

CC1=C(C#N)C(c2ccc3c(N)n[nH]c3c2)C(C#N)=C(C)N1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 10/20 0.62
▸ RPS6KA3 P51812 1/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ DRD5 P21918 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HTR6 P50406 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ PDPK1 O15530 2/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ GABRA1 P14867 1/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ TGFBR1 P36897 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1414765 0.89 MET (0.66) METRPS6KA3SMN1; SMN2POLBMAPK1
Bay-474 SCHEMBL4994862 0.81 MET (0.66) METRPS6KA3SMN1; SMN2POLBMAPK1
SCHEMBL2013768 0.79 MET (0.63) METRPS6KA3SMN1; SMN2POLBMAPK1
SCHEMBL4988283 0.79 MET (0.63) METRPS6KA3SMN1; SMN2POLBMAPK1
SCHEMBL2009485 0.79 MET (0.63) METRPS6KA3SMN1; SMN2POLBMAPK1
SCHEMBL4996153 0.79 MET (0.63) METRPS6KA3SMN1; SMN2POLBMAPK1
SCHEMBL9906867 0.78 MET (0.53) METRPS6KA3SMN1; SMN2POLBMAPK1
SCHEMBL2010519 0.78 MET (0.58) METRPS6KA3SMN1; SMN2POLBMAPK1
SCHEMBL2008387 0.78 MET (0.58) METRPS6KA3SMN1; SMN2POLBMAPK1
SCHEMBL4437474 0.78 MET (0.58) METRPS6KA3SMN1; SMN2POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121608-B1 DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS BAYER IP GMBH (DE) 2012-11-14 — — EP disclosed
US-8198456-B2 e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 — — US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS MET, DMPK, RET MET 1/4885RPS6KA3 146/4885SMN1; SMN2 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback